These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 8350035)

  • 1. Economics of a reduction in smoking: case study from Heartbeat Wales.
    Phillips CJ; Prowle MJ
    J Epidemiol Community Health; 1993 Jun; 47(3):215-23. PubMed ID: 8350035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of the Heartbeat Wales programme over five years on behavioural risks for cardiovascular disease: quasi-experimental comparison of results from Wales and a matched reference area.
    Tudor-Smith C; Nutbeam D; Moore L; Catford J
    BMJ; 1998 Mar; 316(7134):818-22. PubMed ID: 9549451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The SmokingPaST Framework: illustrating the impact of quit attempts, quit methods, and new smokers on smoking prevalence, years of life saved, medical costs saved, programming costs, cost effectiveness, and return on investment.
    O'Donnell MP; Roizen MF
    Am J Health Promot; 2011; 26(1):e11-23. PubMed ID: 21879928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic modeling study.
    Feenstra TL; Hamberg-van Reenen HH; Hoogenveen RT; Rutten-van Mölken MP
    Value Health; 2005; 8(3):178-90. PubMed ID: 15877590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cost-effectiveness analysis of a community pharmacist-based smoking cessation programme in Thailand.
    Thavorn K; Chaiyakunapruk N
    Tob Control; 2008 Jun; 17(3):177-82. PubMed ID: 18285385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preventible smoking deaths.
    Ball KP
    Lancet; 1972 Jan; 1(7743):201. PubMed ID: 4109567
    [No Abstract]   [Full Text] [Related]  

  • 7. Evaluation of the economic impact of California's Tobacco Control Program: a dynamic model approach.
    Miller LS; Max W; Sung HY; Rice D; Zaretsky M
    Tob Control; 2010 Apr; 19 Suppl 1(Suppl_1):i68-76. PubMed ID: 20382654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The economic and social costs of lung cancer and the economics of smoking prevention.
    Godfrey C
    Monaldi Arch Chest Dis; 2001 Oct; 56(5):458-61. PubMed ID: 11887505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of treating nicotine dependence: the Mayo Clinic experience.
    Croghan IT; Offord KP; Evans RW; Schmidt S; Gomez-Dahl LC; Schroeder DR; Patten CA; Hurt RD
    Mayo Clin Proc; 1997 Oct; 72(10):917-24. PubMed ID: 9379693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Predicted effect of smoking cessation of tobacco-related mortality].
    Brønnum-Hansen H
    Ugeskr Laeger; 2000 Oct; 162(43):5772-7. PubMed ID: 11082677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model.
    Lutz MA; Lovato P; Cuesta G
    Hosp Pract (1995); 2012 Feb; 40(1):24-34. PubMed ID: 22406880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost analysis of varenicline versus bupropion, nicotine replacement therapy, and unaided cessation in Nicaragua.
    Lutz MA; Lovato P; Cuesta G
    Hosp Pract (1995); 2012 Feb; 40(1):35-43. PubMed ID: 22406881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impacts of a smoking cessation benefit among employed populations.
    Halpern MT; Dirani R; Schmier JK
    J Occup Environ Med; 2007 Jan; 49(1):11-21. PubMed ID: 17215709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cost-effectiveness analysis of docetaxel in the second-line treatment of non-small cell lung cancer.
    Holmes J; Dunlop D; Hemmett L; Sharplin P; Bose U
    Pharmacoeconomics; 2004; 22(9):581-9. PubMed ID: 15209527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The long-term cost-effectiveness of varenicline (12-week standard course and 12 + 12-week extended course) vs. other smoking cessation strategies in Canada.
    von Wartburg M; Raymond V; Paradis PE
    Int J Clin Pract; 2014 May; 68(5):639-46. PubMed ID: 24472120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The excess cost of acute exacerbations of chronic bronchitis in patients aged 45 and older in England and Wales.
    McGuire A; Irwin DE; Fenn P; Gray A; Anderson P; Lovering A; MacGowan A
    Value Health; 2001; 4(5):370-5. PubMed ID: 11705127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic model of sustained-release bupropion hydrochloride in health plan and work site smoking-cessation programs.
    Halpern MT; Khan ZM; Young TL; Battista C
    Am J Health Syst Pharm; 2000 Aug; 57(15):1421-9. PubMed ID: 10938982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An economic analysis of tobacco elimination policies in Turkey.
    Arslanhan S; Caner A; Helvacioglu K; Saglam I; Teksoz T
    Health Policy; 2012 Jul; 106(2):149-60. PubMed ID: 22473246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimating the public economic consequences of introducing varenicline smoking cessation therapy in South Korea using a fiscal analytic framework.
    Connolly MP; Baker CL; Kotsopoulos N
    J Med Econ; 2018 Jun; 21(6):571-576. PubMed ID: 29376747
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.